SanoLibio GmbH in Liquidation
03.01.2023 – SanoLibio announces the decision to shift operations completely into Thailand and to liquidize SanoLibio GmbH. The decision follows a new positioning strategy to propel the project towards its …
Announcement of a new publication
3.10.2022 – We are dedicated to unearth the composition of the rare cell population in health and in disease with the support of SanoLibio technology. Our latest discovery is a …
SanoLibio in Use
24.05.2022 – SanoLibio announces the commencement of a clinical trial conducted by its partner company Premise Biosystems Co., Ltd. (Thailand) in collaboration with Rama Thibodi Hospital in Bangkok for the …
Announcement of publication in Medical Hypotheses Journal.
20.09.2021 This scientific article represents a hypothetical elaboration about potential use of systemic disease-associated circulating rare cells in comprehension for in-depth cytological analysis at the single cellular level. We denote …
We’ve been named one of @hello tomorrow’s Deep Tech Pioneers!
23.09.2021 We’ve been named one of @hello tomorrow’s Deep Tech Pioneers! Come and meet us at the “Hello Tomorrow Global Summit 2021” along with 3,500 disruptive startups, investors, corporations and …
Announcement of publication of our scientific article on Bone Marrow Damage Assessment by cell-based Liquid Biopsy
01.09.2021 Cyto-hematological investigations conducted by our group using the Walderbach platform in various clinical research tasks has leveraged the discovery of circulating cellular markers to indicate bone marrow damage. Imbalances …
Patent Application – Bone Marrow Damage
20.03.2020 As part of the immanent advancement of cell-based liquid biopsy, we are happy to announce the filing of the latest patent application of the SanoLibio Project introducing the discovery …